Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives
Pierre Costa1, Thierry Grivel2, Naji Gehchan31Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical Division, Suresnes, FranceA...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-04-01
|
| Series: | Patient Preference and Adherence |
| Online Access: | http://www.dovepress.com/tadalafil-once-daily-in-the-management-of-erectile-dysfunction-patient-a3038 |
| _version_ | 1818002533567692800 |
|---|---|
| author | Pierre Costa Thierry Grivel Naji Gehchan |
| author_facet | Pierre Costa Thierry Grivel Naji Gehchan |
| author_sort | Pierre Costa |
| collection | DOAJ |
| description | Pierre Costa1, Thierry Grivel2, Naji Gehchan31Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical Division, Suresnes, FranceAbstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors – sildenafil, tadalafil and vardenafil – are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily. The primary aims of this review are to summarize the patients’ and partners’ viewpoints of ED management with PDE5 inhibitors, and to determine whether once-daily tadalafil can contribute to improving some psychological aspects of ED (such as sexual self-confidence, spontaneity and time concerns) compared with on-demand tadalafil or other PDE5 inhibitors taken by patients with ED.Keywords: erectile dysfunction, once-daily treatment, patient and partner perspectives, phosphodiesterase 5 (PDE5) inhibitor |
| first_indexed | 2024-04-14T03:47:00Z |
| format | Article |
| id | doaj.art-9a193360214c44459e218e8803bcfb16 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-04-14T03:47:00Z |
| publishDate | 2009-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-9a193360214c44459e218e8803bcfb162022-12-22T02:14:12ZengDove Medical PressPatient Preference and Adherence1177-889X2009-04-012009default105111Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectivesPierre CostaThierry GrivelNaji GehchanPierre Costa1, Thierry Grivel2, Naji Gehchan31Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical Division, Suresnes, FranceAbstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors – sildenafil, tadalafil and vardenafil – are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily. The primary aims of this review are to summarize the patients’ and partners’ viewpoints of ED management with PDE5 inhibitors, and to determine whether once-daily tadalafil can contribute to improving some psychological aspects of ED (such as sexual self-confidence, spontaneity and time concerns) compared with on-demand tadalafil or other PDE5 inhibitors taken by patients with ED.Keywords: erectile dysfunction, once-daily treatment, patient and partner perspectives, phosphodiesterase 5 (PDE5) inhibitorhttp://www.dovepress.com/tadalafil-once-daily-in-the-management-of-erectile-dysfunction-patient-a3038 |
| spellingShingle | Pierre Costa Thierry Grivel Naji Gehchan Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives Patient Preference and Adherence |
| title | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives |
| title_full | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives |
| title_fullStr | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives |
| title_full_unstemmed | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives |
| title_short | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives |
| title_sort | tadalafil once daily in the management of erectile dysfunction patient and partner perspectives |
| url | http://www.dovepress.com/tadalafil-once-daily-in-the-management-of-erectile-dysfunction-patient-a3038 |
| work_keys_str_mv | AT pierrecosta tadalafiloncedailyinthemanagementoferectiledysfunctionpatientandpartnerperspectives AT thierrygrivel tadalafiloncedailyinthemanagementoferectiledysfunctionpatientandpartnerperspectives AT najigehchan tadalafiloncedailyinthemanagementoferectiledysfunctionpatientandpartnerperspectives |